腹膜瓣预防机器人辅助根治性前列腺切除加淋巴结清扫后淋巴囊肿:随机对照3期PELYCAN试验
这项研究者发起的双盲3期随机对照试验纳入551例接受经腹膜机器人辅助根治性前列腺切除加盆腔淋巴结清扫的患者,评估双侧腹膜瓣对术后症状性淋巴囊肿的预防作用。意向性分析显示,腹膜瓣使症状性淋巴囊肿从9.1%降至3.7%(p=0.005),无症状淋巴囊肿从27.2%降至10.3%(p<0.001),手术时间延长11分钟(p<0.001)。作者认为腹膜瓣应成为新的标准治疗。
要点
- 腹膜瓣使症状性淋巴囊肿从9.1%降至3.7%(p=0.005)。
- 无症状淋巴囊肿从27.2%降至10.3%(p<0.001)。
- 手术时间延长11分钟(p<0.001),其余并发症无显著差异。
核心结论
- 这是评估腹膜瓣预防淋巴囊肿的最大随机对照试验,达到主要终点,即减少症状性淋巴囊肿。
- 包括无症状淋巴囊肿在内的所有亚组分析结果一致。
- 作者认为,鉴于可减轻患者和医疗系统负担,建立腹膜瓣应成为新的标准治疗。
研究设计与样本
- 研究者发起、前瞻性、平行、双盲、适应性3期随机对照试验。
- 招募时间为2019年9月至2021年12月,记录6个月书面问卷随访。
- 按潜在淋巴囊肿危险因素(扩大盆腔淋巴结清扫、糖尿病、抗凝)和术者分层,采用1:1区组随机化。
- 共筛选860例男性,随机551例。
- 术者在完成最后手术步骤后获知分组。
主要发现
- 意向性分析显示,症状性淋巴囊肿从9.1%降至3.7%(p=0.005)。
- 无症状淋巴囊肿从27.2%降至10.3%(p<0.001)。
- 干预组手术时间延长11分钟(p<0.001)。
- 术后并发症(除外淋巴囊肿)的数量(80 vs 103,p=0.879)和严重程度(p=0.182)无显著差异。
临床怎么用
- 作者认为,建立腹膜瓣应成为新的标准治疗。
- 作者认为,该技术安全且减少淋巴囊肿发生,应成为标准手术。
局限性
- 基于问卷的随访可能是一个局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Symptomatic lymphoceles (SLCs) after transperitoneal robotic-assisted radical prostatectomy with pelvic lymph node dissection (PLND) are common. Evidence from randomised controlled trials (RCTs) on the impact of peritoneal flaps (PFs) on lymphocele (LC) reduction is inconclusive. OBJECTIVE: To show that addition of PFs leads to a reduction of postoperative SLCs. DESIGN, SETTING, AND PARTICIPANTS: An investigator-initiated, prospective, parallel, double-blinded, adaptive, phase 3 RCT was conducted. Recruitment took place from September 2019 until December 2021; 6-month written survey-based follow-up was recorded. Stratification was carried out according to potential LC risk factors (extended PLND, diabetes mellitus, and anticoagulation) and surgeons; 1:1 block randomisation was used. Surgeons were informed about allocation after completion of the last surgical step. INTERVENTION: To create PFs, the ventral peritoneum was incised bilaterally and fixated to the pelvic floor. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was SLCs. Secondary endpoints included asymptomatic lymphoceles (ALCs), perioperative parameters, and postoperative complications. RESULTS AND LIMITATIONS: In total, 860 men were screened and 551 randomised. Significant reductions of SLCs (from 9.1% to 3.7%, p = 0.005) and ALCs (27.2% to 10.3%, p < 0.001) over the follow-up period of 6 mo were observed in the intention-to-treat analysis. Operating time was 11 min longer (p < 0.001) in the intervention group; no significant differences in amount (80 vs 103, p = 0.879) and severity (p = 0.182) of postoperative complications (excluding LCs) were observed. The survey-based follow-up might be a limitation. CONCLUSIONS: This is the largest RCT evaluating PF creation for LC prevention and met its primary endpoint, the reduction of SLCs. The results were consistent among all subgroup analyses including ALCs. Owing to the subsequent reduction of burden for patients and the healthcare system, establishing PFs should become the new standard of care. PATIENT SUMMARY: A new technique-creation of bilateral peritoneal flaps-was added to the standard procedure of robotic-assisted prostatectomy for lymph node removal. It was safe and decreased lymphocele development, a common postoperative complication and morbidity. Hence, it should become a standard procedure.
引用
- Neuberger M, Kowalewski KF, Simon V, et al. Peritoneal Flap for Lymphocele Prophylaxis Following Robotic-assisted Radical Prostatectomy with Lymph Node Dissection: The Randomised Controlled Phase 3 PELYCAN Trial. Eur Urol Oncol. 2023. PMID: 37543465. doi:10.1016/j.euo.2023.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。